Sarepta Sells $174 Million Stake in Arrowhead to Fund Milestone Payment Amid Cash Crunch
Sarepta Therapeutics; Arrowhead Pharmaceuticals; cash crunch; stake sale; milestone payment; RNAi collaboration; SRP-1003; myotonic dystrophy; private block trade
NIH and HHS Cancel Major mRNA Vaccine Research Funding, Citing Lack of Public Trust
NIH; mRNA vaccine; public trust; research funding; BARDA; COVID-19; vaccine hesitancy; RFK Jr.; Jay Bhattacharya; grant cancellation
Merck Begins Layoffs in New Jersey as Part of $3 Billion Cost-Cutting Plan
Merck & Co.; New Jersey; layoffs; pharma industry; cost-cutting; Keytruda; restructuring; WARN notice
Response Pharma: RDX-002 Limits Weight Regain After GLP-1 Therapy – Positive Phase II Results Announced
Response Pharmaceuticals; RDX-002; GLP-1 discontinuation; weight regain; obesity; Phase II clinical trial; postprandial triglycerides; cardiometabolic health; iMTP inhibitor
Hatteras Raises $200M for Two New Funds Following HistoSonics Exit Success
Hatteras Venture Partners; $200M; venture capital; life sciences; early-stage startups; biotech; medtech; HistoSonics exit; fundraising; Hatteras Venture Fund VII; Hatteras Opportunity Fund I
Insmed Secures FDA Approval for First DPP1 Inhibitor in Lung Disease
Insmed; FDA approval; DPP1 inhibitor; Brensocatib; Brinsupri; bronchiectasis; lung disease
Uncertainty Clouds Finances for Payers and Health Systems in Q2 2025
Q2 2025; healthcare financial performance; payers; health systems; uncertainty; Medicaid; Medicare; admissions; policy changes; federal budget; consumer confidence
Fierce Biotech Layoff Tracker 2025: Abata Folds; Generation Lays Off 90% of Staff
biotech layoffs; Abata; Generation; Fierce Biotech Layoff Tracker; 2025; company closure; staff reduction
Eli Lilly Vows Vigorous Defense as Texas Sues Over Alleged Drug Kickbacks
Eli Lilly; Texas Attorney General; kickback scheme; drug prescriptions; Mounjaro; Zepbound; GLP-1 drugs; Medicaid fraud; Free Nurse Program; Support Services Program; Ken Paxton; pharmaceutical litigation
Phase III Study: Perioperative Padcev & Keytruda Combo Significantly Improves Survival in Bladder Cancer
Padcev; Keytruda; enfortumab vedotin; pembrolizumab; phase III; bladder cancer; muscle-invasive bladder cancer; cisplatin-ineligible; perioperative; event-free survival; overall survival